

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

FIRST PATIENT ENROLLMENT IN THE MULTI-CENTER REGISTRATION CLINICAL TRIAL OF GeminiOne® TRANSCATHETER EDGE-TO-EDGE REPAIR SYSTEM IN CHINA

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on November 24, 2022, the Company has enrolled the first patient in the multi-center registration clinical trial of GeminiOne® transcatheter edge-to-edge repair (“**TEER**”) system (the “**System**”). The first procedure was successfully completed by Prof. Xiangbin Pan and his team at Fuwai Yunnan Cardiovascular Hospital. The procedure went smoothly and the overall instrument handling time was only approximately thirty minutes. The registration clinical trial of GeminiOne® TEER system is a prospective, multi-center, single-arm study of assessing the safety and efficacy of the System for treating patients with moderate to severe or severe degenerative mitral regurgitation, led by Prof. Shengshou Hu, member of the Chinese Academy of Engineering. Results from this multi-center registration clinical trial would be included in the Company’s future submission of registration application to the National Medical Products Administration.

GeminiOne® TEER system is an edge-to-edge repair device independently developed by the Company. The product has a unique design, which enables a longer coaptation length while still maintaining smaller implant size and delivery system. Other innovations include its independent leaflet grasp that reduces the complexity of the procedure, auto-locking mechanism that avoids repeatedly lock and unlock during the procedure, as well as multi-angular detachment that copes with a wider range of anatomy.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET GeminiOne® TEER SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, December 4, 2022

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip and Mr. Huacheng Wei as independent non-executive Directors.